The growth of the pharmaceutical industry is changing. Experts in the industry pointed out that the markets for cancer, cardiovascular and anti-infective diseases are huge in scale, rich in variety, and concentrated in patent medicines, so it is easy to find and create new growth points. The future large-scale large-scale pharmaceutical companies are also most likely to be born in these three mainstream markets. .
The three major market prices rose
The market growth ultimately comes from the growth of the quantity or the price increase. On the surface, because the government continues to impose price cuts, market growth seems to have originated only in quantitative growth. But this is not always the case. Studies have shown that from 2004 to the first half of 2006, despite frequent price cuts, the weighted average prices (total drug amount/total amount) of cancer, cardiovascular, and anti-infective mainstream prescription drug markets have not declined, but have risen by nearly 20 percent. %.
Zhang Wei of Hisun Pharmaceutical disclosed that before adjusting the prices of pharmaceutical products, the country had gone to various pharmaceutical companies to conduct research and comprehensively consider factors such as production costs, profit margins, and other inputs. Some of Onsun Pharmaceutical's anti-tumor drugs not only did not lower their prices because of R&D investment and technological transformation, but also increased their prices.
In addition, some experts believe that in the context of price cuts for drugs, the weighted average price has risen. The most likely explanation is that changes in the price of certain drugs have led to changes in the proportion of different drugs used in the market, and the use of medium-to-high-end products has increased. . This also shows that pharmaceutical companies, distribution channels and hospitals are relatively adaptable to prices in the three major areas of cancer, cardiovascular and anti-infection.
Scaled survival
A study in the prescription drug market shows that many anti-infective drug products in China have become generic drugs and their profits are close to the bottom line. However, from 2004 to 2006, the growth of the anti-infective drug market was achieved by a total increase of 40%.
At present, many anti-infective drug companies are taking the "big market sales channels," extending to the domestic small and medium-sized cities and township medical markets, and further promote the increase in sales.
At the same time, new drugs in the field of anti-infective drugs continue to emerge, and a large number of alternative products have been brought to market. Industry experts said: "The facts show that when the profit space is squeezed, the scale can still create profits."
For example, Yangzijiang Pharmaceutical Co., Ltd. has 20 anti-infective products; Harbin Pharmaceutical Group's annual production capacity of antibiotics and intermediates is 3500 tons, and the annual production capacity of powder injections is 2.1 billion; Shanghai Pharmaceutical Group also has nearly 50 antibiotic varieties.
And foreign companies that rely on high-priced brand drugs are no longer the scene. In recent years, hospital antibiotic drug rankings show that only one foreign-funded company is among the top ten companies.
Advantage products support growth
The increase in diseases such as hypertension, hyperlipidemia, heart disease and atherosclerosis has made the cardiovascular sector the second largest market after infection, with an annual market capacity of 15 billion yuan.
Studies have shown that there has been no significant increase in drug consumption in this area, and the weighted average price has continued to rise by 40%. The root cause is the increase in the proportion of drugs used in high-end drugs.
Experts point out that high-priced products in this area are often drugs that have advantages in terms of efficacy-based patents. The Ministry of Health data shows that in China, the number of people with hypertension is as high as 160 million, but only 14% are actually treated.
Most of the more successful companies in this market do not have large production lines, but rely on one or two advantageous products to achieve sustained growth.
New drugs drive profit growth
The excess profits of new anti-cancer drugs have stimulated the pharmaceutical companies to keep up with new products and expand the market through rewarding clinical trials. Since 2004, the weighted average price of the anti-tumor market has increased by 60%.
Zhang Wei stated frankly that anti-tumor drugs in the four major categories of products of Hisun Pharmaceutical are subject to relatively small fluctuations in earnings. It is precisely because this field can obtain more stable returns than other fields. Hisun Pharmaceutical has exerted great efforts in the research and development of new anti-tumor drugs.
AstraZeneca's anti-cancer drug Iressa, the first year of sales revenue is more than 100 million yuan. At present, many pharmaceutical companies are preparing to introduce new anti-tumor drugs. Among multinational companies, Pfizer's SUTENT for kidney cancer and Bayer's NEXAVAR for kidney cell cancer will land in China. Jiangsu Hengrui is also preparing to list Gem Platinum, leucovorin calcium, and the third generation of 5FU compound preparations.
Boston Consulting Group predicts that in 2010, China's prescription drug market is expected to double in size and become the fifth largest consumer of prescription drugs in the world. Industry experts said that this forecast is very optimistic, but it is not a rumor. Zhang Lu, a representative of the Zhejiang pharmaceutical and securities affairs, said: "The future domestic pharmaceutical market is a big piece of cake. We can't keep Jinshan to eat."
The three major market prices rose
The market growth ultimately comes from the growth of the quantity or the price increase. On the surface, because the government continues to impose price cuts, market growth seems to have originated only in quantitative growth. But this is not always the case. Studies have shown that from 2004 to the first half of 2006, despite frequent price cuts, the weighted average prices (total drug amount/total amount) of cancer, cardiovascular, and anti-infective mainstream prescription drug markets have not declined, but have risen by nearly 20 percent. %.
Zhang Wei of Hisun Pharmaceutical disclosed that before adjusting the prices of pharmaceutical products, the country had gone to various pharmaceutical companies to conduct research and comprehensively consider factors such as production costs, profit margins, and other inputs. Some of Onsun Pharmaceutical's anti-tumor drugs not only did not lower their prices because of R&D investment and technological transformation, but also increased their prices.
In addition, some experts believe that in the context of price cuts for drugs, the weighted average price has risen. The most likely explanation is that changes in the price of certain drugs have led to changes in the proportion of different drugs used in the market, and the use of medium-to-high-end products has increased. . This also shows that pharmaceutical companies, distribution channels and hospitals are relatively adaptable to prices in the three major areas of cancer, cardiovascular and anti-infection.
Scaled survival
A study in the prescription drug market shows that many anti-infective drug products in China have become generic drugs and their profits are close to the bottom line. However, from 2004 to 2006, the growth of the anti-infective drug market was achieved by a total increase of 40%.
At present, many anti-infective drug companies are taking the "big market sales channels," extending to the domestic small and medium-sized cities and township medical markets, and further promote the increase in sales.
At the same time, new drugs in the field of anti-infective drugs continue to emerge, and a large number of alternative products have been brought to market. Industry experts said: "The facts show that when the profit space is squeezed, the scale can still create profits."
For example, Yangzijiang Pharmaceutical Co., Ltd. has 20 anti-infective products; Harbin Pharmaceutical Group's annual production capacity of antibiotics and intermediates is 3500 tons, and the annual production capacity of powder injections is 2.1 billion; Shanghai Pharmaceutical Group also has nearly 50 antibiotic varieties.
And foreign companies that rely on high-priced brand drugs are no longer the scene. In recent years, hospital antibiotic drug rankings show that only one foreign-funded company is among the top ten companies.
Advantage products support growth
The increase in diseases such as hypertension, hyperlipidemia, heart disease and atherosclerosis has made the cardiovascular sector the second largest market after infection, with an annual market capacity of 15 billion yuan.
Studies have shown that there has been no significant increase in drug consumption in this area, and the weighted average price has continued to rise by 40%. The root cause is the increase in the proportion of drugs used in high-end drugs.
Experts point out that high-priced products in this area are often drugs that have advantages in terms of efficacy-based patents. The Ministry of Health data shows that in China, the number of people with hypertension is as high as 160 million, but only 14% are actually treated.
Most of the more successful companies in this market do not have large production lines, but rely on one or two advantageous products to achieve sustained growth.
New drugs drive profit growth
The excess profits of new anti-cancer drugs have stimulated the pharmaceutical companies to keep up with new products and expand the market through rewarding clinical trials. Since 2004, the weighted average price of the anti-tumor market has increased by 60%.
Zhang Wei stated frankly that anti-tumor drugs in the four major categories of products of Hisun Pharmaceutical are subject to relatively small fluctuations in earnings. It is precisely because this field can obtain more stable returns than other fields. Hisun Pharmaceutical has exerted great efforts in the research and development of new anti-tumor drugs.
AstraZeneca's anti-cancer drug Iressa, the first year of sales revenue is more than 100 million yuan. At present, many pharmaceutical companies are preparing to introduce new anti-tumor drugs. Among multinational companies, Pfizer's SUTENT for kidney cancer and Bayer's NEXAVAR for kidney cell cancer will land in China. Jiangsu Hengrui is also preparing to list Gem Platinum, leucovorin calcium, and the third generation of 5FU compound preparations.
Boston Consulting Group predicts that in 2010, China's prescription drug market is expected to double in size and become the fifth largest consumer of prescription drugs in the world. Industry experts said that this forecast is very optimistic, but it is not a rumor. Zhang Lu, a representative of the Zhejiang pharmaceutical and securities affairs, said: "The future domestic pharmaceutical market is a big piece of cake. We can't keep Jinshan to eat."
Jiangsu Bailite Transmission Technology Co., Ltd , https://www.nbzsindustrialbelt.com